Axel Haupt

21PUBLICATIONS
28CO-AUTHORS
Predictive and prognostic markersPharmacogenomicsPharmaceutical delivery technologiesEpigenetics (incl. genome methylation and epigenomics)Food properties (incl. characteristics and health benefits)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Aug 17, 2026
Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.

|Jun 02, 2026
Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial.

|Jan 21, 2026
Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept.

Shobha Bhattachar, Lai San Tham, Beth Tidemann-Miller

|Jul 29, 2025
Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids.

Yi Wen, Deven Lemen, Yanzhu Lin

|Jun 24, 2025
Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial.

Corby K Martin, Owen T Carmichael, Susan Carnell

|Jan 06, 2025
Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: An exploratory analysis.

Kieren J Mather, Andrea Mari, Govinda Weerakkody

Pageof 4

Frequent Collaborators

10 joint publications

Tamer Coskun

9 joint publications

Edward Pratt

5 joint publications

Zvonko Milicevic

5 joint publications

Kieren J Mather